Preclinical Development of DuoBody®-CD3xB7H4 – a Novel CD3 Bispecific Antibody for the Treatment of Solid Cancers
Time: 8:30 am
day: Conference Day 1
Details:
- Exploring the preclinical use of CD3xB7H4 in humanised mice
- Analysing bispecific antibody development to treat cancers
